beta
IA Trial Radar
El ensayo clínico NCT06744491 (NFRF) para Inactividad física, Envejecimiento, Envejecimiento saludable, Growth & Development, Diferencias sexuales, Anabolic Sensitivity, Protein Metabolism, Actividad física está aún no recluta. Consulte la vista de tarjeta del Radar de Ensayos Clínicos y las herramientas de descubrimiento de IA para conocer todos los detalles. O haga cualquier pregunta aquí.
Un ensayo coincide con los criterios de filtro
Vista de tarjeta

Oral 'Breath Test' to Measure Anabolic Sensitivity to a Protein Meal Across the Age and Physical Activity Spectrum (NFRF)

Aún no recluta
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el ensayo' para ver y discutir la información del ensayo en el idioma que haya seleccionado.
El estudio clínico NCT06744491 (NFRF) es un ensayo observacional para Inactividad física, Envejecimiento, Envejecimiento saludable, Growth & Development, Diferencias sexuales, Anabolic Sensitivity, Protein Metabolism, Actividad física. Su estado actual es: aún no recluta. Se planea que el reclutamiento se inicie el 20 de diciembre de 2024 hasta que el ensayo reclute a 80 participantes. Dirigido por la Universidad de Toronto, se espera que finalice el 31 de agosto de 2025. Los datos se actualizaron por última vez en ClinicalTrials.gov el 20 de diciembre de 2024.
Resumen
The purpose of this study is to determine how anabolic sensitivity, in response to the ingestion of a liquid protein meal, differs across the lifespan, between biological sexes, and with varying physical activity levels.
Descripción detallada
Skeletal muscle is a dynamic tissue that responds to anabolic (i.e., growth) stimuli such as protein ingestion and exercise. Differences in age and physical activity levels will influence an individual's ability to respond to these anabolic stimuli; this concept is known as anabolic sensitivity. For instance, older and less physically active individuals will display lower anabolic sensitivity (i.e., anabolic resistance) to a bout of exercise or the consumption of protein in comparison to younger, more physically active individuals. Seeing that individuals with anabolic resistance are at a greater risk for losing muscle mass over time, it is important to understand the anabolic sensitivity/resistance of an individual to assess for the efficiency of growth across the health and lifespan, in addition to a potential screen for metabolic alterations that could manifest into changes in lean body and muscle mass.

Traditional methods to assess for skeletal muscle anabolism and protein metabolism requires in-person and invasive research methods (i.e., stable isotope infusions and muscle biopsies) in controlled laboratory or clinical settings. However, there are many risks associated with these invasive procedures and they are not always feasible in all populations (e.g., children, clinical populations, etc..). Our lab has recently developed a non-invasive 13C breath test which employs an oral stable isotope tracer. Our breath test allows us to assess for anabolic sensitivity in response to protein ingestion, by determining how much of the ingested protein was used to build (synthesize) new proteins in our body (i.e., anabolism) or used as a source of energy (through a process called oxidation). As such, the purpose of the present study is to determine how anabolic sensitivity, in response to the ingestion of a liquid protein meal, differs across the lifespan and with varying physical activity levels.

Título oficial

Anabolic Sensitivity Across the Lifespan

Condiciones médicas
Inactividad físicaEnvejecimientoEnvejecimiento saludableGrowth & DevelopmentDiferencias sexualesAnabolic SensitivityProtein MetabolismActividad física
Otros ID del ensayo
  • NFRF
  • 00044004
Número del NCT
Inicio del ensayo (real)
2024-12-20
Última actualización
2024-12-20
Fecha de finalización (estimada)
2025-08-31
Inscripción (prevista)
80
Tipo de estudio
Observacional
Estado general
Aún no recluta
Palabras clave
anabolic sensitivity
aging
growth and development
physical activity
skeletal muscle
stable isotopes
Brazos / Intervenciones
Grupo de participantesIntervención/Tratamiento
Children
Children as defined by maturity offset via age from peak height velocity (aPHV \< -1.0 years).
N/A
Adolescent
Adolescents as defined by maturity offset via age from peak height velocity (aPHV -0.5 to +1.5 years)
N/A
Young Adults
Young adults as defined by chronological age between ages 18 - 35 years
N/A
Older Adults
Older adults as defined by chronological age between ages 60 - 80 years
N/A
Resultado primario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Amino acid oxidation and net protein balance
Amino acid oxidation and net protein balance assessed by oral 1-13C Leucine tracer. Net protein balance is derived from the difference between amino acid intake (known) and total amino acid oxidation over the 6h post-prandial measurement period.
6 Hours
Criterios de elegibilidad

Criterios de edad
Niño, Adulto, Adulto mayor
Edad mínima
8 Years
Criterios de sexo
Todos
Admisión de voluntarios sanos
  • Healthy will be defined as screened by the PAR-Q+ (The Physical Activity Readiness Questionnaire for everyone)
  • Chronological age for Healthy Young (age: 18-35 years) or Older (age: 60-80 years) adults
  • Chronological age between 8 to 16 years, with maturity offset < -1 year from age of Peak Height Velocity (aPHV) for children and between -0.5 to +1.5 years from aPHV in adolescent participants
  • BMI between normal to overweight (18.5 - 29.9 kg/m2)

  • Regular use of nonsteroidal anti-inflammatory dugs (with the exception of daily low-dose aspirin)
  • use of anticoagulants
  • use of a walker, cane, or assistive walking device
  • infectious or gastrointestinal disease
  • inability to comply with study protocol (e.g., unable to track diet)
  • regular tobacco use
  • self-reported illicit drug use (e.g., growth hormone, testosterone, etc.)
  • diagnosed chronic illness (e.g., type 2 diabetes, heart disease, thyroid disease)
  • pregnant
  • hormonal replacement therapy
Parte responsable del ensayo
Daniel Moore, Investigador principal, Professor, Muscle Physiology, University of Toronto
Contactos centrales del ensayo
Contacto: Daniel R Moore, PhD, 4169464088, [email protected]
Contacto: Hugo JW Fung, PhD Candidate, [email protected]
1 Sitios del ensayo en 1 países

Ontario

Goldring Center for High Performance Sport, Toronto, Ontario, M5S 2C9, Canada
Hugo JW Fung, PhD Candidate, Contacto, 416-946-5620, [email protected]